Myriad Genetics Inc

Name: Myriad Genetics Inc standardized financial statements, quarterly
Creator: Listed

MYGNNasdaqCIK 899923HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$190.7m, Q2 FY2026

Operating income−$38.9m, Q2 FY2026

Net income−$43.2m, Q2 FY2026

Myriad Genetics Inc, income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	192	197	202	212	213	211	196	213	206	210	200	191
Cost of revenue	$m	57.6	61.6	64.6	64.4	63.5	59.7	61.7	61.3	61.9	63.0	62.8	63.7
Gross profit	$m	not reported	not reported	138	147	150	151	134	152	144	147	138	127
Research and development	$m	24.0	21.0	24.9	27.1	28.5	32.2	27.5	25.6	28.2	25.5	27.1	25.0
Selling, general and administrative	$m	136	144	141	145	139	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Operating income	$m	(60.1)	(31.4)	(27.9)	(36.5)	(20.0)	(39.0)	(29.0)	(329)	(23.3)	(5.7)	(30.7)	(38.9)
Interest expense	$m	1.0	0.9	0.5	0.8	0.8	0.7	0.8	1.5	3.8	4.4	4.1	4.1
Income tax	$m	0.1	(1.1)	0.1	(0.5)	0.9	3.4	(29.3)	(0.1)	1.2	(1.0)	0.0	0.6
Net income	$m	(61.3)	(31.2)	(26.0)	(36.7)	(22.1)	(42.5)	(0.1)	(331)	(27.4)	(7.9)	(34.1)	(43.2)
Diluted EPS	$ per share	(0.75)	not reported	(0.29)	(0.41)	(0.24)	not reported	0.00	(3.57)	(0.29)	not reported	(0.36)	(0.46)
Basic EPS	$ per share	(0.75)	not reported	(0.29)	(0.41)	(0.24)	not reported	0.00	(3.57)	(0.29)	not reported	(0.36)	(0.46)

Balance sheet

Cash and equivalents$115.2m, Q2 FY2026

Long-term debt$120.7m, Q2 FY2026

Shareholders' equity$303.9m, Q2 FY2026

Myriad Genetics Inc, balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	76.0	132	96.9	92.4	99.9	102	91.8	74.4	145	150	124	115
Current assets	$m	265	314	290	292	293	298	287	284	345	333	313	289
Total assets	$m	1,149	1,147	1,111	1,085	1,081	1,028	1,006	677	728	707	674	639
Current liabilities	$m	209	156	146	149	154	164	151	200	148	134	130	131
Total liabilities	$m	466	363	351	345	350	327	301	289	355	339	336	335
Long-term debt	$m	38.5	38.5	38.7	38.8	39.0	39.6	59.3	0.0	120	120	120	121
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	0.0	not reported	59.4	not reported	not reported	not reported	not reported
Short-term borrowings	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	683	783	760	741	732	701	705	388	373	368	337	304

Cash flow

Operating cash flow−$8.3m, Q2 FY2026

Myriad Genetics Inc, cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(22.1)	(54.7)	(18.6)	2.6	0.7	6.6	(16.3)	(13.6)	21.1	10.6	(15.7)	(8.3)
Capital expenditure	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Share repurchases	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)94.80m, Q2 FY2026

Myriad Genetics Inc, shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	80.7	81.3	81.7	81.9	89.9	90.6	90.9	91.4	92.5	93.1	93.7	94.8

Shares outstanding: 95.65m at Jul 28, 2026, from the cover of the 10-Q filed Jul 31, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. Listed shows no prices and gives no investment advice.